ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) BEYOND LDLR TARGETING: FOCUS ON GLUCOSE METABOLISM

被引：0
|
作者：
Balzarotti, Gloria [1 ]
Tibolla, Gianpaolo [1 ]
Ruscica, Massimiliano [1 ]
Di Cairano, Eliana [1 ]
Perego, Carla [1 ]
Catapano, Alberico Luigi [1 ,3 ]
Norata, Giuseppe Danilo [1 ,2 ]
机构：
[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[2] Bassini Hosp, Sisa Ctr, Milan, Italy
[3] Irccs Multimed, Milan, Italy
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.332
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG204
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [1] ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) IN OBESITY AND METABOLIC SYNDROME: BEYOND LDLR TARGETING
    Balzarotti, G.
    Tibolla, G.
    Ruscica, M.
    Stramba-Badiale, M.
    Catapano, A. L.
    Norata, D. G.
    ATHEROSCLEROSIS, 2016, 252 : E223 - E223
  • [2] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [3] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [4] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Bao, Xuhui
    Liang, Yongjun
    Chang, Hanman
    Cai, Tianji
    Feng, Baijie
    Gordon, Konstantin
    Zhu, Yuekun
    Shi, Hailian
    He, Yundong
    Xie, Liyi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [5] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Xuhui Bao
    Yongjun Liang
    Hanman Chang
    Tianji Cai
    Baijie Feng
    Konstantin Gordon
    Yuekun Zhu
    Hailian Shi
    Yundong He
    Liyi Xie
    Signal Transduction and Targeted Therapy, 9
  • [6] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [7] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [8] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
  • [9] Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
    Cammisotto, Vittoria
    Baratta, Francesco
    Simeone, Paola G.
    Barale, Cristina
    Lupia, Enrico
    Galardo, Gioacchino
    Santilli, Francesca
    Russo, Isabella
    Pignatelli, Pasquale
    ANTIOXIDANTS, 2022, 11 (03)
  • [10] Role and regulation of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in the small intestine
    Leblond, Francois
    Precourt, Louis-Philippe
    Delvin, Edgard
    Elchebly, Mounib
    Seidah, Nabil
    Ziv, Ehud
    Levy, Emile
    FASEB JOURNAL, 2008, 22
12345